Intermittent Fasting: A User-Friendly Method for Type 2 Diabetes Mellitus (2024)

  • Journal List
  • Cureus
  • v.13(11); 2021 Nov
  • PMC8653959

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

Intermittent Fasting: A User-Friendly Method for Type 2 Diabetes Mellitus (1)

Link to Publisher's site

Cureus. 2021 Nov; 13(11): e19348.

Published online 2021 Nov 8. doi:10.7759/cureus.19348

PMCID: PMC8653959

PMID: 34909309

Monitoring Editor: Alexander Muacevic and John R Adler

Mahreen Saeed,Intermittent Fasting: A User-Friendly Method for Type 2 Diabetes Mellitus (2)1 Moeez Ali,2 Tehreem Zehra,3 Saiyed Ali Haider Zaidi,4 and Rihab Tariq1

Author information Article notes Copyright and License information PMC Disclaimer

Abstract

Type 2 diabetes mellitus (T2DM) is an alarmingly rising disorder characterized mainly by insulin resistance and hyperglycemia. Due to the impairment of glucose homeostasis, most subjects present with elevated serum glucose levels, which can lead to several complications, including hospitalizations and even death. Diet quality and quantity are at the heart of its pathogenesis; hence,for the management of this condition, a technique known as intermittent fasting (IF) has been an area of interest for researchers. Different fasting regimens, including alternate-day fasting, religious fasting, and time-restricted fasting, have proven to be of strategic importance for glycemic control due to their physiologic effects. According to case studies and randomized trials, therapeutic fasting has been shown to reverse insulin resistance, resulting in the discontinuance of insulin therapy while maintaining blood sugar levels.

Studies on IF have demonstrated their efficacy in glycemic control and other metabolic parameters, including reducingvisceral fat and controlling inflammatory mediators and markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), but control in obesity is its most significant effect as it acts as a risk factor for T2DM. Several case studies have shown a reduction in elevated hemoglobin A1c (HbA1c) levels in subjects after fasting, which some believe is due to sirtuin-6 (SIRT6) proteins. SIRT6 proteins are believed to be responsible for blood glucose homeostasis and insulin resistance reversal by increasing its sensitivity. This family of proteins is increased after fasting; hence, further research in this area will help researchers better understand its mechanism of action and potential therapeutic effects on T2DM. With an alarming increase in the incidence of T2DM around the world, a cost-effective strategy is required to control the disease with easy patient compliance, and IF might prove to be the solution.

Keywords: type 1 diabetes mellitus, type 2 diabetes mellitus, intermittent fasting, fasting, weight loss and obesity, glycated hemoglobin (hba1c), therapeutic fasting, religious fasting

Introduction and background

Intermittent fasting (IF), also known as periodic fasting or intermittent energy reduction, is proportionally a new dietary proposal to weight regulation and includes inventive regular caloric intake within a small and specific period[1]. Intermittent fasting has achieved a lot of regards in terms of weight reduction. IF is of several categories and mainly cycles between periods of caloric restriction and eating[2]. Different patterns of intermittent fasting have been proposed, the most popular of which is the alternate-day fasting, which usually involves a fasting day followed by a feeding day. These patterns could be followed for days to weeks to months in order to regulate weight and maintain blood glucose levels [3].

Time-restricted fasting is also one of the patterns of intermittent fasting, which usually involvesfood intake in a particular period (3-12 hours) and fasting for the remaining hours of the day. Ramadan fasting is an excellent illustration of time-restricted fasting. During the holy month of Ramadan, Muslims from all over the world fast during daylight, followed by the consumption of food and drinks after sunset until the first light of the sun[4].

Diabetes mellitus is a long-standing metabolic disease, which signalizes raised sugar levels in the blood. The disease progressively leads to damage to various other organs such as the heart, kidney, eyes, nerves, and other vessels. According to the World Health Organization (WHO), over 90% of cases are type 2 diabetes mellitus (T2DM), a condition that is marked by decreased production of insulin by beta cells of the pancreas and variable magnitude of insulin resistance[5,6]. The incidence of this disease is multiplying worldwide predominantly due to environmental, genetic, and metabolic factors[7-11]. The risk factor for T2DM could be categorized into modifiable risk factors, such as decreased physical activity, raised BMI, and unhealthy diet, and non-modifiable risk factors, such as age, ethnicity, and positive family history[12,13].

The objective of this article is to highlight the use of IF for the management of T2DM. Substantial data is available on this subject in the form of case studies and other types of literature mentioned in the subsequent parts of the article. This article will feature the types of IF, their physiological effects on diabetics, and studies involving human subjects for T2DM management strategy.

Review

Adaptive responses of humans to intermittent fasting

Fasting is deliberate self-abnegation from food, and intermittent fasting (IF) is a methodology in which an eating regimen proposes consumption of food only within a specified time of the day, succeeded by fasting[14]. All formats of IF mainly restrict carbohydrate intake, which results in reduced energy requirement by the body and increases hunger. This primarily occurs due tocompensatory hormonal changes regulating body weight[15]. As defined by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes, a reduction in carbohydrate intake is considered to be a useful treatment of type 2 diabetes (T2D) in standard medical nutrition therapy[16]. The aforementioned approach precedes even the development of exogenous insulin in 1921 as a novel treatment modality. It is premised on the evidence that carbohydrates are the macronutrient with the highest insulin and macronutrient indices[17].

In humans, glucose is primarily stored in the liver in the form of glycogen. Depending on the physical and exertion activity, there is a 20% or greater reduction in serum glucose levels during fasting. Consequently, non-hepatic glucose, fat-derived ketone bodies, and free fatty acids are utilized as an alternative energy source[18]. Although most tissues can metabolize fatty acids for energy, during persistently long durations of fasting, the brain uses β-hydroxybutyrate and acetoacetate in addition to glucose. It is interesting to note that after hepatic exhaustion of glycogen, approximately 80 g/day of glucose is generated by gluconeogenesis. According to a study, the ketone bodies, free fatty acids, and gluconeogenesis allow the majority of human beings to survive 30 or more days without food[19]. The degree to which fasting affects human metabolism and health outcomes depends on the type of fasting, which is mentioned in Table1[20].

Table 1

Types of fasting and their structure

TypeFasting regimen
Alternate-day fasting regimenComprises alternate eating days (ad libitum consumption of food and beverages) with alternating fasting days (abstaining from energy-providing food and beverages)
Time-restricted food consumptionAd libitum food intake at different intervals in a particular time frame
Modified fasting regimenPermits ad libitum eating five days of the week and restricting food in the remaining two to only 20%–25% of energy requirement
Religious fastingA fast practiced by Muslims in their holy month of Ramadan starting a little before sunrise to sunset. Eating is permitted before their morning prayer time and after the sunset. Thus, the average Ramadan fasting time around the world is about 12 hours
Other religious fastingFasting practices for religious or spiritual purposes

Open in a separate window

In China, a prospective, single-blind randomized controlled trial (RCT) was performed between December 2015 and December 2016 [21]. The subjects were randomly allocated to receive either a low carbohydrate diet (LCD) or a low-fat diet (LFD). Before the intervention, all subjects underwent a one-week washout period to diminish the effect of background diets on the study [22]. The effect of restricting the diet was remarkable. Compared with the baseline, hemoglobin A1c (HbA1c) levels in both the LCD group and the LFD group decreased significantly (0.63% ± 1.18% and 0.31% ± 0.70%, respectively). Furthermore, when compared with the baseline, the dosage of insulin used in the two groups also decreased significantly after the intervention (p < 0.05) [21].

In addition to this, another randomized non-inferiority trial was conducted between April 7, 2015, and September 7, 2017, at the University of South Australia [23]. In this study, 137 adults (n = 137) with type 2 diabetes were randomized 1:1 to parallel diet groups (intermittent energy restriction [n = 70] or continuous energy restriction [n = 67]). The intervention mainly restricted diet (500-600 kcal/day) followed for two nonconsecutive days per week (participants followed their usual diet for the other five days) or a continuous energy restriction diet (1200-1500 kcal/day) followed for seven days per week for 12 months [23]. The notable outcome was the change in hemoglobin A1c (HbA1c) level, with equivalence prespecified by a 90% confidence interval (CI) margin of ±0.5%. The secondary outcome was weight reduction with equivalence set at ±2.5 kg (±1.75 kg for fat mass loss and ±0.75 kg for fat-free mass loss) [23]. This data proves that dietary intervention is a strategy to manage T2DM, as it can reduce the burden on islet cells and thus improve blood glucose levels, lipid profiles, and cognitive status [24-26].

In addition to this, an animal study provided mechanistic clues for a better understanding of the effects of IF on glycemic control. It suggested that IF may slow or even reverse the development of type 2 diabetes (T2D) [27]. Mice were controlled with a fasting-mimicking diet (alternate-day fasting), which presented with a rise in the number of insulin-generating pancreatic beta cells. Differentiated cells in the pancreas decreased initially in the fasting state, and interestingly, the pancreatic transitional cells and beta cells increased in the non-fasting state after the initial fasting. This proves that in animal studies, intermittent energy restriction appears to be equally effective as, if not more effective than, continuous energy restriction for the reduction of disease risk factors [27].

Religious fasting

For physical and spiritual benefits, fasting is an essential part of several religions and cultures around the world. For example, fasting for Muslims in the holy month of Ramadan is an important religious practice. Adult Muslims fast from a little before sunrise until sunset, abstaining from any type of food or fluid intake, including oral medications and cigarette smoking[20]. According to a 2012 meta-analysis of 35 studies, weight changes were seen in subjects fasting during Ramadan. The subjects aged between 18 and 58 presented with a 1.24 kg reduction during this practice; this trend was noticed in 21 (60%) studies[28]. Another meta-analysis of 30 cohort studies investigated the changes in physiological biomarkers in fasting men and women in addition to weight loss[29]. The results showed that fasting blood glucose and low-density lipid (LDL) levels in both genders were reduced after Ramadan as compared with before it. It is interesting to note that the males experienced a significant reduction in their weight, triglycerides (TG), and total cholesterol levels and that the females experienced a rise in their high-density lipid (HDL) cholesterol levels[10]. Moreover, studies have also reported attenuated concentrations of pro-inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) associated with Ramadan fasting[30,31]. In addition, glycemic control is also improved during Ramadan fasting, and recent studies provided evidence suggesting that there are a 0.5 point decrease in hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes after fasting during Ramadan[32].

In addition to Ramadan fasting, other religious fasts are also practiced globally. For example, a study involving 448 patients from hospitals in Utah found that the followers of The Church of Jesus Christ of Latter-day Saints who routinely fasted demonstrated lower fasting glucose levels, lower weight, and lower diabetes prevalence with an odds ratio (OR) of 0.41 and 95% confidence interval (CI) of0.17-0.99[33]. Substantial observational data is available on different types of fasting regimens, including religious fasting; however, participation of these individuals in clinical trials and studies remains low due to their reservations. It is suggested that a better reach-out program to these individuals is needed and that more epidemiological studies can improve our insight on the different types of fasting. Also, dietary nutritionists should be involved in these studies to identify the dietary changes adopted by the subjects and how they vary among individuals.

Therapeutic fasting, obesity, and type 2 diabetes mellitus

The symptoms of diabetes can be managed using medications; however, medications cannot completely cure the underlying condition[34]. As noted in an open-label Diabetes Remission Clinical Trial (DiRECT), caloric limitation and weight management are important factors for T2D. The DiRECT study demonstrated remission and maintenance of T2D via caloric restriction (~840 calories/day) and weight loss in a non-insulin-dependent diabetic population[35]. According to a case report, in June 2016, at age 54 years, a woman with a 15-year history of T2D and using metformin 1000 mg twice a day presented with elevated HbA1c levels (8.7%)[36]. The subject initiated a ketogenic diet (KD) and IF in July 2018 when her HbA1c was 9.3%. Interestingly, after a few months (in March 2019), her HbA1c, weight, and BMI changed from 9.3% to 6.4%, 55.3to 54.9 kg, and 22.3 to 22.1 kg/m2, respectively[36]. Four weeks after her dietary changes, the patient reportedly discontinued all her medications, including metformin, a statin, and an antihypertensive drug, and at the same time, she improved her glycemic control[36]. On follow-up, the patient expressed her plans to maintain her KD and IF, which she currently continues. This is one of the strong evidence on how dietary changes, especially IF, can help in glycemic control in diabetic patients as the patient was seen to improve her glycemic control without using most of her medicine as mentioned above and was able to significantly reduce her HbA1c levels by fasting.

Another interesting case series involving three patients with T2D discusses the physiological changes seen after adopting dietary changes. Patient details and characteristics are summarized in Table2[37].

Table 2

Patient details and characteristics

T2D: type 2 diabetes; HTN: hypertension; CKD: chronic kidney disease; RCC: renal cell carcinoma

SexAgeOnset of T2DHistory/comorbiditiesFasting regimen
Patient 1Male40Present; 20 years priorHTN, hypercholesterolemiaThree times/week for seven months
Patient 2Male52Present; 25 years priorCKD, RCC (nephrectomy in 2004), HTN, hypercholesterolemiaThree times/week for 11 months
Patient 3Male67Present; 10 years priorHTN, hypercholesterolemiaAlternating days for 11 months

Open in a separate window

Several changes were noted after the initiation of IF in all three subjects, which are summarized in Table3[36].

Table 3

Glycemic and other changes noted on patient follow-up

IU: international units

Initial HbA1c (%, mmol/mol)Final HbA1c (%, mmol/mol)Initial weight (kg)Final weight (kg)Initial diabetic medicationsFinal diabetic medicationsTime to discontinuation of insulin (days)
Patient 111, 96.77, 5383.873.8Insulin glargine 58, insulin aspart 22, canagliflozin 300 mg, metformin 1 gCanagliflozin 300 mg5
Patient 27.2, 55.26, 42.16150.4Insulin lispro mix 25–38/32 IU 25None18
Patient 36.8, 50.86.2, 44.397.188.1Metformin 1000 mg, insulin lispro mix 25–30/20 IUNone

Open in a separate window

The subjects were only allowed to consume dinner on fasting days; however, low carbohydrate lunch and dinner were consumed on non-fasting days. In addition to this, the patients were examined twice a month, and their laboratory results were recorded[37]. The most remarkable development of this case series was noted to be the discontinuation of insulin in all three patients, which strengthens the evidence for IF as an effective management modality for patients with T2D [37].

Another ongoing research in this area involves sirtuin proteins, particularly sirtuin-6 (SIRT6), which is believed to have a potential therapeutic effect on insulin resistance[19]. According to animal studies, it does this by enhancing insulin sensitivity and decreasing fasting blood glucose levels[38-40]. Both short-term and long-term caloric restriction has presented with elevated SIRT6 levels in animal data, which draws the researcher’s attention towardthe role of IF in disease modification[41].

Although all patients suffering from T2D are not overweight, IF regimens mainly focus on bodyweight reduction as obesity is a known precipitating factor for T2D. Bariatric surgery is an effective strategy to manage obesity; however, it is limited by its accessibility, potential for complications, and invasive nature[15]. Although modifications in one’s lifestyle are highly recommended to manage T2D, attaining the desired glycemic control seems very complicated in obese patients, and this leads to the recommendation of therapeutic fasting. This restricts the caloric intake in obese patients and can help manage T2D without any invasive technique such as Bariatric surgery.

Conclusions

The objective of this review article is to shed light on intermittent fasting as a lifestyle modification in patients with T2D and its outcomes. The effects of intermittent fasting on diabetics deserve more than a casual mention as it precipitates notable physiologic changes helping in the condition. Different studies carried out on people practicing religious fasting presented a noteworthy reduction in their weight in addition to reduced LDL and TG levels after fasting. Decreased HbA1c and lowered pro-inflammatory mediators such as TNF-α and IL-6 were also seen. As apparent from the mentioned studies, the patient compliance for this approach was very high in people who already practiced religious fasting. Also, in patients with complete novelty to this methodology, the feedback was very positive, and several patients remarked on enjoying being actively involved in the process of managing their diabetes.

Dietary modifications such as LCD and LFD have also been found to be effective in the treatment of obesity, and apart from significantly reducing weight, it can also effectively improve blood lipid and insulin resistance. Educating patients on the advantages of fasting in the management of T2D may aid in the remission of the disease and curtail the use of pharmacological interventions. Further studies and more clinical trials will help researchers understand the exact mechanism of IF on diabetics, and there is substantial data available to encourage research in this area. Furthermore, if validated, this approach will revolutionize our understanding and management strategy towardthis rising and chronic disease.

Notes

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Footnotes

The authors have declared that no competing interests exist.

References

1. The effects of intermittent energy restriction on indices of cardiometabolic health. Antoni R, Johnston KL, Collins AL, and Robertson MD. Endocr. 2014;2014 [Google Scholar]

2. Intermittent fasting: is the wait worth the weight? Stockman MC, Thomas D, Burke J, Apovian CM. Curr Obes Rep. 2018;7:172–185. [PMC free article] [PubMed] [Google Scholar]

3. A randomized pilot study comparing zero-calorie alternate-day fasting to daily caloric restriction in adults with obesity. Catenacci VA, Pan Z, Ostendorf D, et al. Obesity (Silver Spring) 2016;24:1874–1883. [PMC free article] [PubMed] [Google Scholar]

4. Options for controlling type 2 diabetes during Ramadan. Almalki MH, Alshahrani F. Front Endocrinol (Lausanne) 2016;7:32. [PMC free article] [PubMed] [Google Scholar]

5. Type 2 diabetes: principles of pathogenesis and therapy. Stumvoll M, Goldstein BJ, van Haeften TW. Lancet. 2005;365:1333–1346. [PubMed] [Google Scholar]

6. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Weyer C, Bogardus C, Mott DM, Pratley RE. J Clin Invest. 1999;104:787–794. [PMC free article] [PubMed] [Google Scholar]

7. The effect of diabetes-specific enteral nutrition formula on cardiometabolic parameters in patients with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Ojo O, Weldon SM, Thompson T, Crockett R, Wang XH. Nutrients. 2019;11:1905. [PMC free article] [PubMed] [Google Scholar]

8. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Diabetes Care. 2005;28:1092–1100. [PubMed] [Google Scholar]

9. Effect of oral nutritional supplements with sucromalt and isomaltulose versus standard formula on glycaemic index, entero-insular axis peptides and subjective appetite in patients with type 2 diabetes: a randomised cross-over study. Angarita Dávila L, Bermúdez V, Aparicio D, et al. Nutrients. 2019;11:1477. [PMC free article] [PubMed] [Google Scholar]

10. Epigenetics and epigenomics: implications for diabetes and obesity. Rosen ED, Kaestner KH, Natarajan R, Patti ME, Sallari R, Sander M, Susztak K. Diabetes. 2018;67:1923–1931. [PMC free article] [PubMed] [Google Scholar]

11. National Health Service (NHS) Digital and Healthcare Quality Improvement Partnership. National Diabetes Audit, 2015-2016 Report 1: care processes and treatment targets. http://www.content.digital.nhs.uk/catalogue/PUB23241/nati-diab-rep1-audi-2015-16.pdf 2017

12. Type 2 diabetes. Chatterjee S, Khunti K, Davies MJ. Lancet. 2017;389:2239–2251. [PubMed] [Google Scholar]

13. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. NCD Risk Factor Collaboration (NCD-RisC) Lancet. 2016;387:1513–1530. [PMC free article] [PubMed] [Google Scholar]

14. The role of low-calorie diets and intermittent fasting in the treatment of obesity and type-2 diabetes. Zubrzycki A, Cierpka-Kmiec K, Kmiec Z, Wronska A. J Physiol Pharmacol. 2018;69 [PubMed] [Google Scholar]

15. Long-term persistence of hormonal adaptations to weight loss. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. N Engl J Med. 2011;365:1597–1604. [PubMed] [Google Scholar]

16. Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Davies MJ, D'Alessio DA, Fradkin J, et al. Diabetes Care. 2018;41:2669–2701. [PMC free article] [PubMed] [Google Scholar]

17. Dietary treatment of diabetes mellitus in the pre-insulin era (1914-1922) Westman EC, Yancy WS Jr, Humphreys M. Perspect Biol Med. 2006;49:77–83. [PubMed] [Google Scholar]

18. Fasting: molecular mechanisms and clinical applications. Longo VD, Mattson MP. Cell Metab. 2014;19:181–192. [PMC free article] [PubMed] [Google Scholar]

19. Heterothermy in growing king penguins. Eichhorn G, Groscolas R, Le Glaunec G, Parisel C, Arnold L, Medina P, Handrich Y. Nat Commun. 2011;2:435. [PubMed] [Google Scholar]

20. Metabolic effects of intermittent fasting. Patterson RE, Sears DD. Annu Rev Nutr. 2017;37:371–393. [PubMed] [Google Scholar]

21. The effect of low-carbohydrate diet on glycemic control in patients with type 2 diabetes mellitus. Wang LL, Wang Q, Hong Y, et al. Nutrients. 2018;10:661. [PMC free article] [PubMed] [Google Scholar]

22. Reliability of an interview approach to the Functional Independence Measure. Daving Y, Andrén E, Nordholm L, Grimby G. Clin Rehabil. 2001;15:301–310. [PubMed] [Google Scholar]

23. Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. Carter S, Clifton PM, Keogh JB. JAMA Netw Open. 2018;6:0. [PMC free article] [PubMed] [Google Scholar]

24. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Ley SH, Hamdy O, Mohan V, Hu FB. Lancet. 2014;383:1999–2007. [PMC free article] [PubMed] [Google Scholar]

25. Blood glucose, diet-based glycemic load and cognitive aging among dementia-free older adults. Seetharaman S, Andel R, McEvoy C, Dahl Aslan AK, Finkel D, Pedersen NL. J Gerontol A Biol Sci Med Sci. 2015;70:471–479. [PMC free article] [PubMed] [Google Scholar]

26. Dietary DHA and health: cognitive function ageing. Cardoso C, Afonso C, Bandarra NM. Nutr Res Rev. 2016;29:281–294. [PubMed] [Google Scholar]

27. Fasting-mimicking diet promotes Ngn3-driven β-cell regeneration to reverse diabetes. Cheng CW, Villani V, Buono R, et al. Cell. 2017;168:775–788. [PMC free article] [PubMed] [Google Scholar]

28. Islamic fasting and weight loss: a systematic review and meta-analysis. Sadeghirad B, Motaghipisheh S, Kolahdooz F, Zahedi MJ, Haghdoost AA. Public Health Nutr. 2014;17:396–406. [PMC free article] [PubMed] [Google Scholar]

29. Does Ramadan fasting alter body weight and blood lipids and fasting blood glucose in a healthy population? a meta-analysis. Kul S, Savaş E, Öztürk ZA, Karadağ G. J Relig Health. 2014;53:929–942. [PubMed] [Google Scholar]

30. Interleukin-6, C-reactive protein and biochemical parameters during prolonged intermittent fasting. Aksungar FB, Topkaya AE, Akyildiz M. Ann Nutr Metab. 2007;51:88–95. [PubMed] [Google Scholar]

31. Intermittent fasting during Ramadan attenuates proinflammatory cytokines and immune cells in healthy subjects. Faris MA, Kacimi S, Al-Kurd RA, Fararjeh MA, Bustanji YK, Mohammad MK, Salem ML. Nutr Res. 2012;32:947–955. [PubMed] [Google Scholar]

32. Fasting during Ramadan and associated changes in glycaemia, caloric intake and body composition with gender differences in Singapore. Yeoh EC, Zainudin SB, Loh WN, et al. https://pubmed.ncbi.nlm.nih.gov/26292948/ Ann Acad Med Singap. 2015;44:202–206. [PubMed] [Google Scholar]

33. Usefulness of routine periodic fasting to lower risk of coronary artery disease in patients undergoing coronary angiography. Horne BD, May HT, Anderson JL, et al. Am J Cardiol. 2008;102:814–819. [PMC free article] [PubMed] [Google Scholar]

34. Can diabetes be surgically cured? long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Brethauer SA, Aminian A, Romero-Talamás H, et al. Ann Surg. 2013;258:628–636. [PMC free article] [PubMed] [Google Scholar]

35. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lean ME, Leslie WS, Barnes AC, et al. Lancet. 2018;391:541–551. [PubMed] [Google Scholar]

36. Therapeutic use of intermittent fasting and ketogenic diet as an alternative treatment for type 2 diabetes in a normal weight woman: a 14-month case study. Lichtash C, Fung J, Ostoich KC, Ramos M. BMJ Case Rep. 2020;13:0. [PMC free article] [PubMed] [Google Scholar]

37. Therapeutic use of intermittent fasting for people with type 2 diabetes as an alternative to insulin. Furmli S, Elmasry R, Ramos M, Fung J. BMJ Case Rep. 2018;2018:0. [PMC free article] [PubMed] [Google Scholar]

38. SIRT6 as a potential target for treating insulin resistance. Tang W, Fan Y. Life Sci. 2019;231:116558. [PubMed] [Google Scholar]

39. SIRT6-mediated transcriptional suppression of Txnip is critical for pancreatic beta cell function and survival in mice. Qin K, Zhang N, Zhang Z, et al. Diabetologia. 2018;61:906–918. [PMC free article] [PubMed] [Google Scholar]

40. SIRT6 protects against pathological damage caused by diet-induced obesity. Kanfi Y, Peshti V, Gil R, et al. Aging Cell. 2010;9:162–173. [PubMed] [Google Scholar]

41. Regulation of SIRT6 protein levels by nutrient availability. Kanfi Y, Shalman R, Peshti V, et al. FEBS Lett. 2008;582:543–548. [PMC free article] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

Intermittent Fasting: A User-Friendly Method for Type 2 Diabetes Mellitus (2024)
Top Articles
Latest Posts
Article information

Author: Mrs. Angelic Larkin

Last Updated:

Views: 6555

Rating: 4.7 / 5 (47 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Mrs. Angelic Larkin

Birthday: 1992-06-28

Address: Apt. 413 8275 Mueller Overpass, South Magnolia, IA 99527-6023

Phone: +6824704719725

Job: District Real-Estate Facilitator

Hobby: Letterboxing, Vacation, Poi, Homebrewing, Mountain biking, Slacklining, Cabaret

Introduction: My name is Mrs. Angelic Larkin, I am a cute, charming, funny, determined, inexpensive, joyous, cheerful person who loves writing and wants to share my knowledge and understanding with you.